Benitec Biopharma (NASDAQ:BNTC) Research Coverage Started at HC Wainwright

HC Wainwright started coverage on shares of Benitec Biopharma (NASDAQ:BNTC) in a report published on Monday morning, MarketBeat reports. The brokerage issued a buy rating and a $28.00 target price on the biotechnology company’s stock.

Other equities research analysts also recently issued reports about the stock. Oppenheimer assumed coverage on shares of Benitec Biopharma in a research report on Wednesday, October 16th. They set an “outperform” rating and a $35.00 target price for the company. Guggenheim reissued a “buy” rating and issued a $17.00 price objective on shares of Benitec Biopharma in a research note on Tuesday, December 3rd. JMP Securities lifted their target price on Benitec Biopharma from $16.00 to $18.00 and gave the company a “market outperform” rating in a research report on Monday, October 14th. Piper Sandler reissued an “overweight” rating on shares of Benitec Biopharma in a research report on Friday, October 18th. Finally, Robert W. Baird began coverage on Benitec Biopharma in a research note on Friday, December 13th. They set an “outperform” rating and a $30.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $24.43.

Benitec Biopharma Stock Performance

Shares of NASDAQ:BNTC opened at $11.84 on Monday. Benitec Biopharma has a 52-week low of $2.69 and a 52-week high of $13.29. The business’s 50 day simple moving average is $10.73 and its two-hundred day simple moving average is $9.38. The firm has a market cap of $274.88 million, a P/E ratio of -4.17 and a beta of 0.88.

Insiders Place Their Bets

In related news, Director Suvretta Capital Management, L bought 42,000 shares of the company’s stock in a transaction on Tuesday, December 3rd. The shares were purchased at an average cost of $9.60 per share, for a total transaction of $403,200.00. Following the completion of the purchase, the director now directly owns 7,957,365 shares in the company, valued at $76,390,704. The trade was a 0.53 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 1.30% of the company’s stock.

Hedge Funds Weigh In On Benitec Biopharma

Several institutional investors have recently bought and sold shares of BNTC. GAMMA Investing LLC raised its position in shares of Benitec Biopharma by 20.3% in the third quarter. GAMMA Investing LLC now owns 6,540 shares of the biotechnology company’s stock valued at $60,000 after purchasing an additional 1,102 shares during the period. Acuta Capital Partners LLC bought a new stake in Benitec Biopharma during the 3rd quarter valued at $274,000. Simplify Asset Management Inc. purchased a new stake in shares of Benitec Biopharma during the second quarter worth $358,000. Geode Capital Management LLC boosted its holdings in shares of Benitec Biopharma by 31.3% in the third quarter. Geode Capital Management LLC now owns 83,987 shares of the biotechnology company’s stock worth $772,000 after acquiring an additional 20,012 shares during the period. Finally, Nantahala Capital Management LLC purchased a new position in shares of Benitec Biopharma in the second quarter valued at $5,881,000. Hedge funds and other institutional investors own 52.19% of the company’s stock.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.